• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Innovative strategies and new insights for the treatment of stage III non-small cell lung cancer.

作者信息

Cortiula Francesco, Desai Aakash, Menis Jessica, Filippi Andrea R

机构信息

Department of Oncology, University Hospital of Udine, Udine, Italy.

Department of Radiation Oncology (Maastro), Maastricht University Medical Centre (+), GROW School for Oncology and Reproduction, Maastricht, Netherlands.

出版信息

Front Oncol. 2024 Nov 4;14:1503613. doi: 10.3389/fonc.2024.1503613. eCollection 2024.

DOI:10.3389/fonc.2024.1503613
PMID:39558955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11571060/
Abstract
摘要

相似文献

1
Editorial: Innovative strategies and new insights for the treatment of stage III non-small cell lung cancer.社论：治疗Ⅲ期非小细胞肺癌的创新策略与新见解
Front Oncol. 2024 Nov 4;14:1503613. doi: 10.3389/fonc.2024.1503613. eCollection 2024.
2
mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.I 期-III 期非小细胞肺癌的突变检测、治疗和生存：CancerLinQ Discovery 数据库回顾性分析。
Future Oncol. 2024;20(28):2083-2096. doi: 10.1080/14796694.2024.2347826. Epub 2024 Jun 25.
3
The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential biomarker.III期非小细胞肺癌临床参数与可切除性之间的关联，以及N2淋巴结负荷与肺免疫预后指数评分的组合作为一种潜在生物标志物。
Transl Lung Cancer Res. 2023 Jan 31;12(1):79-95. doi: 10.21037/tlcr-22-642. Epub 2023 Jan 13.
4
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.新辅助度伐利尤单抗联合化疗后序贯辅助度伐利尤单抗治疗可切除的II期和III期非小细胞肺癌患者的III期双盲安慰剂对照研究的设计与原理：爱琴试验
Clin Lung Cancer. 2022 May;23(3):e247-e251. doi: 10.1016/j.cllc.2021.09.010. Epub 2021 Oct 10.
5
Role of chemotherapy in stages I to III non-small cell lung cancer.化疗在Ⅰ至Ⅲ期非小细胞肺癌中的作用。
Chest. 1999 Dec;116(6 Suppl):509S-516S. doi: 10.1378/chest.116.suppl_3.509s.
6
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments.十年来 III 期非小细胞肺癌的多学科治疗方法：从放射治疗优化到创新的全身治疗
Cancers (Basel). 2022 Nov 20;14(22):5700. doi: 10.3390/cancers14225700.
7
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.免疫治疗时代可切除的Ⅲ-N2期非小细胞肺癌（NSCLC）的管理
Cancers (Basel). 2021 Sep 26;13(19):4811. doi: 10.3390/cancers13194811.
8
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.早期非小细胞肺癌（NSCLC）的免疫治疗：当前证据和观点。
Curr Oncol. 2023 Mar 27;30(4):3684-3696. doi: 10.3390/curroncol30040280.
9
Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data.III期非小细胞肺癌中未进行分期PET/CT与生存率降低相关：来自LUCAS项目真实世界数据的见解
Transl Lung Cancer Res. 2024 Jul 30;13(7):1495-1504. doi: 10.21037/tlcr-24-108. Epub 2024 Jul 15.
10
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.新辅助免疫治疗时代可切除Ⅲ期非小细胞肺癌管理的最新综述
Cancers (Basel). 2024 Mar 27;16(7):1302. doi: 10.3390/cancers16071302.

本文引用的文献

1
Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials.治疗临床试验中代表性不足的不可切除 III 期非小细胞肺癌患者。
Cancer Treat Rev. 2024 Sep;129:102797. doi: 10.1016/j.ctrv.2024.102797. Epub 2024 Jul 3.
2
Perioperative Nivolumab in Resectable Lung Cancer.可切除肺癌的围手术期纳武利尤单抗。
N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926.
3
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.阿来替尼治疗可切除阳性非小细胞肺癌。
N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532.
4
A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer.不可切除的 III 期非小细胞肺癌的未来展望
Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1455-1460. doi: 10.1016/j.ijrobp.2023.11.005. Epub 2023 Dec 27.
5
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.EGFR 突变型早期 NSCLC 的围手术期治疗策略：当前证据与未来挑战。
J Thorac Oncol. 2024 Feb;19(2):199-215. doi: 10.1016/j.jtho.2023.09.1451. Epub 2023 Sep 30.
6
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.阿特珠单抗辅助化疗用于可切除 II-IIIA 期非小细胞肺癌的总生存期：一项随机、多中心、开放标签、III 期试验（IMpower010）。
Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17.
7
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
8
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
9
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.PACIFIC试验的五年生存结果：III期非小细胞肺癌放化疗后使用度伐利尤单抗治疗
J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.
10
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.